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POLYMORPHOUS LIGHT ERUPTION
SOME UNUSUAL REACTIONS IN ULTEAVIOLET LIGHT TEST SITES*
E1)WJN J. LEVY, MA)., MILTON M. CAHN, M.D. AND
BERTRAM SHAFFER, M.D.
Patients who suffer from polymorphous light eruption usually develop a normal
erythema reaction followed by pigmentation in test sites exposed to hot quartz
ultraviolet light.
However, in some patients with polymorphous light eruption papules may be
artificially reproduced in test sites (1). Intense exposure to hot quartz ultraviolet
light in these individuals, initially produces erythema which is indistinguishable
from the erythema seen in control subjects ("normal erythema"). This is followed
by a more intense erythema in the test sites, preliminary to the onset of the
papular response ("preliminary intense erythema") (table I).
This preliminary intense erythema differs qualitatively from the normal
erythema in the following mariner:
1. It is of greater intensity.
2. It reaches maximum intensity in 48 to 96 hours. Normal erythema reaches
maximum intensity in 24 hours.
3. It remains at maximum intensity for 7 to 10 days. Normal erythema usually
remains at greatest intensity for 48 hours.
4. It is not replaced by pigmentation. Normal erythema is usually replaced
by pigmentation.
In a group of twenty-seven patients tested with hot quartz ultraviolet light on
the upper back, a characteristic papular response was produced iii eight, while
other unusual reactions developed in four. This paper deals with these unusual
reactions.
Case I—R.T., a sixty year old white man developed typical polymorphous light eruption
each summer for the past eight years. He was first tested March 19, 1955 with graded ex-
posures of hot quartz ultraviolet light from one to eight erythema doses on 2.5 cm. square
areas on the upper back. A normal erythemic response developed in each test site (i.e.
erythema did not differ in appearance from that seen in controls). However, the erythema
did not fade, so that when seen one month later, it had persisted in the test sites with un-
diminished intensity. On May 27, 1955, following a prolonged intense sunlight exposure, he
developed typical polymorphous light eruption on all exposed sites—face, hands, "V" of
neck. No papules appeared in test sites which had been protected from exposure. When last
observed, October 1, 1955, the erythema was still present in those original test sites which
had received four or more erythcma doses (Fig. 1). A biospy specimen from one of these
test sites showed a non-specific dermatitis.
Case II—J.H., a fifty-seven year old white man had a history of polymorphous light
eruption each summer for the past twelve years. He was given graded exposures from one-
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FIG. 1. Case I. Persistent erythema in test sites on the back, seven months after
exposure to graded doses o? hot quartz ultraviolet light. Finger pressure has been applied
to one area to demonstrate erythema.
half to eight erythema doses of hot quartz ultraviolet light to 5 cm. square test sites on the
upper back on March 18, 1954. Administration of chioroquine was started one week later.
A normal erythemic response occurred in test sites, but was not replaced by pigmentation
nor did papules develop. Chloroquine suppressed polymorphous light eruption in this pa-
tient throughout the summer (2). However, erythema persisted in all test areas which had
received three or more erythema doses of ultraviolet light, and was still present on Septem-
ber 15, 1954. He was seen again October 15, 1954, and all erythema in test areas had disap-
peared. Chloroquine was stopped on October 15, 1954. This patient was seen again in Jan-
uary, 1955, and despite lack of re-exposure to sunlight, a recurrence of erythema was noted
in all test sites which had received three or more erythema doses of hot quartz ultraviolet
light ten months previously.
Comment: These two patients had prolonged persistent erythema, with lack
of pigmentation, in test sites. Chloroquine apparently did not alter this erythema.
Cese III—E.C., a thirty-one year old white man had a history of polymorphous light
eruption for the past three summers. Hot quartz ultraviolet light testing to 2.5 cm. square
areas on the upper back were done on March 18, 1955. Preliminary intense erythema, fol-
lo\ved by papules developed in test sites. These papules persisted for two weeks, then dis-
appeared. In July, 1955 after prolonged sunlight exposure, he developed typical lesions of
polymorphous light eruption on the face, "V" of neck, and back of hands. A papular erup-
tion also recurred in test sites which previously had received four or more erythema doses,
although these areas were not exposed to sunlight. (Fig. 2).
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FIG. 2. Case III. Recurrence of a papular eruption in hot quartz ultraviolet light
test sites.
Comment: Sunlight not only produced polymorphous light eruption in exposed
areas, but also resulted in the recurrence of a papular eruption in previous ultra-
violet light test sites which were not re-exposed.
Case IV—R.C., a twenty-seven year old white man gave a history of polymorphous light
eruption for the past two summers. He was first seen in July, 1955, with an erythematous
papular eruption on the parts of the body which had been exposed to intense sunlight. He
was given graded exposures of hot quartz ultraviolet to 2.5 cm. square test sites on the
upper back. These resulted in a normal sunburn reaction; no altered erythemic reaction or
papules appeared. He avoided sunlight and the eruption on exposed areas faded.
One month later, after sunlight exposure, the patient again developed typical poiy-
morphous light eruption. However, the previously tested areas on the upper back, which
had not been exposed to sunlight, now developed a preliminary intense erythema followed
by papules.
Comment: Concomitant with a flare of polymorphous light eruption in exposed
body areas, a papular eruption also appeared in non-exposed test sites. Initial
testing in these sites had failed to produce any eruption.
These effects were compared with the reactions to ultraviolet light in normal
subjects. In May 1955, twenty normal white men were given hot quartz ultra-
violet light exposures to 2.5 cm. square areas on the upper back. Graded doses
from one-half to eight erythema doses were delivered by a hot quartz ultraviolet
thLAJ
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light lamp. The normal erythemic response was noted: erythema first appeared
in four to eight hours; maximum intensity was noted in nineteen subjects in
twenty-four to forty-eight hours, and in one subject in ninety-six hours. All
showed pigmentation, following the erythema. Despite intense summer sunlight
exposure to test sites and to other body areas, an inflammatory papular eruption
did not appear.
DISCUSSION
The normal reaction of the skin to ultraviolet light in the sunburn spectrum
(2900—3200 A) is erythema followed by pigmentation. Within four to six hours
after exposure reddening begins and it reaches maximum intensity in twenty-
four to forty-eight hours, at which time pigmentation begins. Normal variations
in this reaction depend on duration and intensity of exposure, and individual
factors such as complexion and epidermal thickness.
Erythema is the macroscopic manifestation of dilatation of the minute blood
vessels of the corium. Since the wave lengths of the sunburn spectrum do not
penetrate beneath the epidermis in any substantial amount, the erythematous
response cannot be a direct effect of ultraviolet light on these vessels. The cry-
thema must result from the action on these blood vessels, of some agent released
by the epidermal cells when they absorb the ultraviolet energy (3). The quantity
of ultraviolet radiation determines the degree of the photochemical reaction which
releases vasodilator substances. While the nature of these released dilator sub-
stances is as yet unknown, it is now generally accepted that these are not hista-
mine or histamine-like substances (4, 5).
Persistent erythema, as represented by Cases I and II, has not been previously
reported as occuring in ultraviolet light test areas in patients with polymorphous
light eruption. It may represent a chronic dilatation of the minute blood vessels
of the corium, as a result of vascular damage from ultraviolet light. In Case i[
erythema persisted for at least seven months in those sites which had received
four or more erythema doses of hot quartz ultraviolet light, while in Case II
erythema persisted for six months, despite the fact that chloroquine concurrently
administered suppressed polymorphous light eruption. The erythema faded
while the patient was still taking chloroquine, but recurred four months later at
a time when chloroquine had been discontinued for three months.
Certain features were noted about this persistent erythema in test sites which
differentiate it from the preliminary intense erythema which precedes a papular
response. These features are:
a. The persistent erythema remained undiminished in intensity, and remained
for several months. The preliminary intense erythema lasts seven to ten days
before onset of papules.
b. Chloroquine had no suppressive effect on the persistent erythema.
In patients with polymorphous light eruption, chloroquine suppresses the
disease, as well as the preliminary intense erythema and papular reaction in
test sites. This tends to substantiate our previously cited opinion (6) that chloro-
quine and probably other antimalarials prevent polymorphous light eruption not
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NORMAL PERSON-3 NORMAL ERYTHEMA y- PIGMENTATION CHLOROQUINE
NO
PATIENT WITH
EFFECT
CHLOROQUINE
POLYMORPHOUS ORMAL ERY THEM A *PRELlMINARY > PAPULES SUPPRESSES
LIGHT INTENSE ERYTHEMA PHOTO-ALLERGIC
ERUPTION RESPONSE
*-PHOTOALLERGIC RESPONSE—;
NORMAL ERYTHEMA *PERSISTENT ERYTHEMA CHLOROQUINE
NO
EFFECT
Table I. Reactions to Hol Quarlz Ultraviolet light in Test Sites of Normal Individoals
and of Patients with Potymorphous Light Eruplioo
by acting as sun screens but by suppressing the typical specific (photoallergic)
reaction that constitutes this disease. When the reaction is not of this specific
type then chloroquine will not act (Table I).
Our observations indicate that spontaneous appearance of papules in a pre-
viously tested non-exposed site may occur with subsequent clinical exposure
whether or not the original testing resulted in papules. In Case III each flare of
the clinical eruption was accompanied by the appearance of a similar eruption in
previously reactive test sites. In Case IV, we were unable to reproduce the erup-
tion experimentally; however, one month later, coincident with the appearance
of polymorphous light eruption on uncovered body areas following sunlight
exposure, papules appeared in previously tested, but presently unexposed, test
sites. Epstein cites two similar cases. (7).
rfhese cases suggest that polymorphous light eruption is a photoallergic disease.
In Case III, a previously sensitized skin area reacts to an eliciting exposure at a
distant site, almost at once. In Case IV, an incubation period presumably ensues
before the sensitizing substance causes a reaction. The nature of this sensitizing
substance is unknown; it has been hypothesized that proantigen, a precursor
substance present in the skin of a photoallcrgic person, is transformed to antigen,
under the influence of irradiation. (7)
Passive transfer studies on the sera of twelve patients with pclymorphous
light eruption were negative. Further work is in progress using patients' white
cells for passive transfer studies.
SUMMARY AND CONCLU5ION5
The appearance of erythematous papules in test sites exposed to hot quartz
ultraviolet light, in some patients with polymorphous light eruption, is well
known. Other unusual reactions in test sites occurred in four of twenty-seven
patients with polymorphous light eruption.
There was persistence of erythema in test sites for seven months following a
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single initial exposure to ultraviolet light in one patient. In a second patient,
erythema persisted in test sites for six months, faded, then spontaneously re-
curred. Chloroquine did not alter this reaction.
The significance of this persistent and recurrent erythema is not known. It
may represent vascular damage from ultraviolet light.
In two patients, typical polymorphous light eruption following sunlight ex-
posure was accompanied by the appearance of papules in previously tested sites,
which were not re-exposed. Prior intense ultraviolet light exposures in the same
test areas had resulted in no observable reaction in one case, although a typical
papular response was noted in the other case.
These unusual papular reactions suggest that polymorphous light eruption is
a true photoallergic disease.
Chloroquine does not act as a sun filtering agent in patients with polymorphous
light eruption, but may act by suppressing the specific photoallergic response.
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DISCUSSION
DR. THEODORE CORNBLEET (Chicago, Ill.): The number and kinds of responses
to light are multiple and various. At present our knowledge is fragmentary and
mostly built upon clinical observation. I think it therefore premature to attempt
a classification, even a rudimentary working one. I believe, too, it would be better
to avoid the use of the term "allergy" to characterize these reactions. Calling
these latter by some name, such as "allergy" about which we have already built
up some concept, is a kind of delusion.
In one of the patients in the group described, chloroquine was shown not to
act as a sun-screen. Nevertheless, chloroquine does have potent screening prop-
erties over a considerable part of the ultraviolet spectrum. This one patient, it
seems to me, does not gainsay chloroquine's preventive action as a sun-screen in
other cases.
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DR. EnwIN J. LEVY (in closing): I thank Dr. Cornbleet for his interesting
comments. I should like to explain why we feel that chioroquine does not act as
a sun screen. We have shown (Polymorphous Light Eruption: The Effect of
Chioroquine Phosphate in Modifying Reactions to Ultraviolet Light. J. Invest.
Dermat., 26: 201—207, 1956) that chioroquine does not alter the normal sunburn
reaction but it does protect against polymorphous light eruption. Since both are
produced by rays in the same spectral region, it would appear that the action is
not that of a sun screening agent or both would be inhibited.
Experimentally, chloroquine does not alter the quantity of ultraviolet light
required for erythema production in normal individuals or in persons with
polymorphous light eruption; but it does suppress the papular reaction in pa-
tients with polymorphous light eruption. Thus, here too its action is not that of
a sun screen.
I would like to show one slide (see Fig. 2 above reference). A study of the
ultraviolet light absorption spectrum for chioroquine shows minimal absorption
between 2800 A and 3100 A. However, the action spectrum for erythema produc-
tion in normal human skin shows a maximum in this same region. Thus, chioro-
quirie does not block those rays which are responsible for normal erythema.
Chioroquine has a peak absorption for ultraviolet light in the spectral region
above 3100 A. However, the rays responsible for the altered reaction of erythema
and papules in our patients are in t.he spectral region below 3100 A.
